Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Caitlin M O'Connor
Affiliation
ORCID
Career Start Year
2017
Papers
15
H Index
8
Expertise
CM4AI Collaborator
PMID
Paper Title
Journal Title
Published Year
36788429
Small-Molecule-Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death.
Mol Cancer Ther
2023
37644036
Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.
Nat Commun
2023
37166997
PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis.
J Clin Invest
2023
34921012
Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.
Cancer Res
2022
36328247
Biased holoenzyme assembly of protein phosphatase 2A (PP2A): From cancer to small molecules.
J Biol Chem
2022
31541192
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
Oncogene
2020
32315618
Selective PP2A Enhancement through Biased Heterotrimer Stabilization.
Cell
2020
32482664
Splice of Life for Cancer: Missplicing of PPP2R5A by Mutant SF3B1 Leads to MYC Stabilization and Tumorigenesis.
Cancer Discov
2020
33027304
The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.
PLoS One
2020
30796164
Protein phosphatase 2A Aα regulates Aβ protein expression and stability.
J Biol Chem
2019
31562245
Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45).
J Biol Chem
2019
31142515
The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.
Cancer Res
2019
29107183
Therapeutic targeting of PP2A.
Int J Biochem Cell Biol
2018
30021885
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Sci Transl Med
2018
28504649
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
J Clin Invest
2017
1 - 15 of 15
Column Actions
Search
Recommended Authors
Collaborators
Goutham Narla
The University of Michigan Medical School ann arbor
Co-authored papers
15
Jaya Sangodkar
University of Michigan ann arbor
Co-authored papers
8
Analisa DiFeo
Co-authored papers
6
Daniel Leonard
Co-authored papers
5
Rita A Avelar
Co-authored papers
4
Zhizhi Wang
Co-authored papers
4
Wenqing Xu
Co-authored papers
4
Abbey L Perl
Co-authored papers
4
Sudeh Izadmehr
Co-authored papers
4
Danica D Wiredja
Co-authored papers
3
David L Brautigan
Co-authored papers
3
Daniela Schlatzer
Co-authored papers
3
Matthew D Galsky
Co-authored papers
3
Shozeb Haider
Co-authored papers
3
Rita Tohme
Co-authored papers
2
Janna Kiselar
Co-authored papers
2
Nilesh Zaware
Co-authored papers
2
Caroline C Farrington
Co-authored papers
2
Michael Ohlmeyer
Atux Iskay LLC
Co-authored papers
2
Derek J Taylor
Case Western Reserve University
Co-authored papers
2
Daniel C McQuaid
Co-authored papers
1
Neil S Dhawan
Co-authored papers
1
Anne-Claude Gingras
Lunenfeld-Tanenbaum Research Institute
Co-authored papers
1
Blake E Smith
Co-authored papers
1
Avi Ma'ayan
Icahn School of Medicine at Mount Sinai
Co-authored papers
1
Sahar Mazhar
Co-authored papers
1
Shen Yao
Co-authored papers
1
Qiaonan Duan
Co-authored papers
1
Marcin Cieslik
Co-authored papers
1
Eric Yuan
Co-authored papers
1
1 - 30